The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The SERCA pump as a therapeutic target: Making a “smart bomb” for prostate cancer
Open accessAbstract
Prostate cancer is uniformly fatal once it has spread outside of the prostate gland. Prostate cancers have a remarkably low proliferative rate, which may in part explain their relative unresponsiveness to conventional antiproliferative chemotherapy. New therapies for prostate cancer that activate proliferation independent cell death are therefore needed. The endoplasmic reticulum (ER) has emerged as an organelle that plays a major role in cell signaling pathways, cellular response to stress and cellular activation of apoptosis. In this review, the SERCA pump is identified as an ER protein whose normal function is required by all cells and represents a potential therapeutic target for cancer therapy. Sustained SERCA inhibition by agents such as thapsigargin results in activation of ER-stress response and simultaneous activation of apoptotic pathways within the ER and the mitochondria. Due to the SERCA pump's critical role in normal cellular metabolism, agents like thapsigargin directed toward inhibiting SERCA function would likely produce significant toxicity to normal cells and, therefore, must be selectively targeted to cancer sites. The cytotoxicity of thapsigargin can be attenuated, however by coupling to a targeting peptide to produce an inactive prodrug that is only activated by prostate cancer specific proteases such as the serine protease prostate-specific antigen (PSA). PSA-activated thapsigargin prodrugs have been characterized that are selectively toxic to PSA-producing prostate cancer cells in vitro and in vivo. These prodrugs are currently undergoing preclinical evaluation as potential targeted therapy for prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase
Harding, H. P., Zhang, Y., & Ron, D. (1999) · Nature · doi:10.1038/16729 · Cited by 3,310
Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response
Bertolotti, A., Zhang, Y., Hendershot, L. M., Harding, H. P., & Ron, D. (2000) · Nature Cell Biology · doi:10.1038/35014014 · Cited by 2,860
Cited by
Mitochondrial and endoplasmic reticulum calcium homeostasis and cell death
Marchi, S., Patergnani, S., Missiroli, S., Morciano, G., Rimessi, A., Wieckowski, M. R., Giorgi, C., & Pinton, P. (2018) · Cell Calcium · doi:10.1016/j.ceca.2017.05.003 · Cited by 695
Calcium and cancer: targeting Ca2+ transport
Monteith, G. R., McAndrew, D., Faddy, H. M., & Roberts-Thomson, S. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2171 · Cited by 676
Calcium Pumps in Health and Disease
Brini, M., & Carafoli, E. (2009) · Physiological Reviews · doi:10.1152/physrev.00032.2008 · Cited by 676
What made sesquiterpene lactones reach cancer clinical trials?
Ghantous, A., Gali-Muhtasib, H., Vuorela, H., Saliba, N. A., & Darwiche, N. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.06.002 · Cited by 615
Calcium in tumour metastasis: new roles for known actors
Prevarskaya, N., Skryma, R., & Shuba, Y. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3105 · Cited by 605
Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay
Aits, S., Kricker, J., Liu, B., Ellegaard, A.-M., Hämälistö, S., Tvingsholm, S., Corcelle-Termeau, E., Høgh, S., Farkas, T., Holm Jonassen, A., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1063871 · Cited by 450
Ion channels and the hallmarks of cancer
Prevarskaya, N., Skryma, R., & Shuba, Y. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.01.005 · Cited by 448
Prevarskaya, N., Zhang, L., & Barritt, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.05.006 · Cited by 355
Patergnani, S., Danese, A., Bouhamida, E., Aguiari, G., Previati, M., Pinton, P., & Giorgi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218323 · Cited by 350
Targeting the endoplasmic reticulum-stress response as an anticancer strategy
Healy, S. J. M., Gorman, A. M., Mousavi-Shafaei, P., Gupta, S., & Samali, A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.064 · Cited by 309
The sarcoplasmic Ca2+-ATPase: design of a perfect chemi-osmotic pump
Møller, J. V., Olesen, C., Winther, A.-M. L., & Nissen, P. (2010) · Quarterly Reviews of Biophysics · doi:10.1017/s003358351000017x · Cited by 284
Mitochondrial Cholesterol Contributes to Chemotherapy Resistance in Hepatocellular Carcinoma
Montero, J., Morales, A., Llacuna, L., Lluis, J. M., Terrones, O., Basañez, G., Antonsson, B., Prieto, J., García-Ruiz, C., Colell, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6161 · Cited by 276
Ion channel expression as promising cancer biomarker
Lastraioli, E., Iorio, J., & Arcangeli, A. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.12.016 · Cited by 187
Demethoxycurcumin Is A Potent Inhibitor of P-Type ATPases from Diverse Kingdoms of Life
Dao, T. T., Sehgal, P., Tung, T. T., Møller, J. V., Nielsen, J., Palmgren, M., Christensen, S. B., & Fuglsang, A. T. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163260 · Cited by 25
Metadata
- Authors
- Denmeade, S. R., & Isaacs, J. T.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 4
- Issue
- 1
- Pages
- 21-29
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2015710917
- Cited by
- 244
- References
- 2
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.